EUCTR2006-001193-25-DE进行中（未招募）不适用
A 4 week randomised, double blind, placebo controlled, parallel group,phase II, PoP study to assess the efficacy and safety of AZD1981 in adultpatients with asthma. - PoPEYE
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Provision of ICF (Informed Consent Form) could be obtained at an information
- •visit prior to Visit 1 or at Visit 1 (according to local regulations), but before any
- •study related procedures has been performed.
- •2. Men and post menopausal or surgically sterilized women, aged 18-60 years.
- •Women will be considered post menopausal if they have been amenorrheic for at
- •least 12 months, and an FSH plasma concentration within the post menopausal
- •range as defined by the laboratory.
- •3. Minimum of 6 month’s documented history of asthma according to the ATS
- •definition (ATS 1987).
- •4. Daily use of =400 µg inhaled GCS during 30 days prior to Visit 1.
- •5. FEV1 =60 - <100% of predicted normal value pre-bronchodilator.
- •6. Reversible airway obstruction either according to the reversibility test performed
- •at Visit 1, or as historic data found in medical record (not older than 2 years)
- •Reversibility is defined as an increase in FEV1 of =12% relative baseline and
- •=200 mL after an inhalation of in total 1 mg Bricanyl Turbuhaler. If not fulfilled at
- •Visit 1, criterion No 11 should be fulfilled at Visit 2.
- •7. The patient must not have had a clinically important asthma exacerbation, as
- •judged by the investigator, one month before Visit 1.
- •8. A positive skin prick test to airway allergens (at least one) such as: pollen from
- •birch, grass, or mugwort, animal fur for example dog, cat, horse, or house dust
- •mite at Visit 1 or as historic data found in medical records not older than 2 years.
- •9. Able to read and write and use electronic devices.
- •10. Use of as-needed medication at least 4 times during the last week of the run-in
- •11. If the reversibility criterion is not met at Visit 1 (either from historic data or
- •from the spirometry measurement) the patient must either show an increase in
- •FEV1 of =12% relative baseline and =200 mL after an inhalation of in total 1 mg
- •Bricanyl Turbuhaler or show a variation in PEF of at least 20% on at least 2 days
- •during the run-in period. This should be calculated as follows: (max PEF - min
- •PEF) / max PEF (all values from the same day).
- •12. The patient must not have taken more than 12 inhalations of as-needed medication
- •on any single day during the run-in period.
- •13. The patient must not have had a clinically important asthma exacerbation, as
- •judged by the investigator, during the run-in period.
- •14. Patients must not have used 8 inhalations or more of as-needed medication/24
- •hours on more than 2 days/week (any 7 days period) during the run-in period.
- •15. The patient must not have used iGCS during the run-in period.
- •16. No clinical relevant abnormal findings in clinical chemistry, haematology, FSH
- •(females only), urinalysis, which, in the opinion of the investigator, may put
- •patient at risk because of his/her participation in the study.
- •17. Provision of informed consent for pharmacogenetic research
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Inability to tolerate withdrawal of asthma therapy as required for the study.
- •2. Hospitalisation for asthma within the last 2 years prior to Visit 1.
- •3. Respiratory infection significantly affecting the asthma, as judged by the
- •investigator, within 30 days prior to Visit 1.
- •4. Any of the following:
- •- current smoker,
- •- patient with a history of smoking for more than 10 pack years (one pack year= 1
- •pack (20 cigarettes) per day for 1 year or equivalent),
- •- ex-smoker since less than 1 year.
- •5. Body Mass Index (BMI) <18 kg/m 2 and body weight <50 kg.
- •6. A history of additional risk factors for Torsade de pointes (eg, heart failure,
- •hypokalemia, family history of Long QT syndrome).
- •7. Use of concomitant medications that prolong the QT/QTc interval other than
- •terbutaline or albuterol.
- •8. Use of ß -blocker medication (including eye-drops)
- •9. Pregnancy or breast feeding.
- •10. Any significant disorder (eg, cardiovascular, pulmonary (other than asthma),
- •gastrointestinal, hepatic, renal, neurological, musculosceletal, infectious,
- •endocrine, metabolic, malignant, psychiatric, major physical impairment) which,
- •in the opinion of the investigator, either put the patient at risk because of
- •participating in the study or may influence the results of the study, or the patients
- •ability to participate in the study.
- •11. Any clinical relevant abnormal findings in physical examination, pulse, blood
- •pressure or ECG at Visit 1, which, in the opinion of the investigator, may put
- •patient at risk because of his/her participation in the study.
- •12. Previous randomisation of treatment into the present study, see Section 3.5.
- •13. Planned hospitalisation during the course of the study.
- •14. Suspected poor capability to follow instructions of the study, as judged by the
- •investigator.
- •15. Past or present alcohol or drug abuse.
- •16. Involvement in the planning and conduct of the study (applies to both AstraZeneca
- •staff and staff at the study site).
- •17. Patients currently on immunotherapy, or who have had a course within the last
- •18. Participation in another clinical study involving an investigational product within
- •3 months before Visit 1.
研究者
相似试验
进行中（未招募）
1 期
A 4 week randomised, double blind, placebo controlled, parallel group, phase II, PoP study to assess the efficacy and safety of AZD1981 in adult patients with asthma.AsthmaEUCTR2006-001193-25-GBAstraZeneca AB22
进行中（未招募）
不适用
A 4 week randomised, double blind, placebo controlled, parallel group,phase II, PoP study to assess the efficacy and safety of AZD1981 in adultpatients with asthma.AsthmaEUCTR2006-001193-25-DKAstraZeneca AB110
进行中（未招募）
不适用
A 4 week randomised, double blind, placebo controlled, parallel group,phase II, PoP study to assess the efficacy and safety of AZD1981 in adultpatients with asthma.AsthmaEUCTR2006-001193-25-SEAstraZeneca AB110
进行中（未招募）
不适用
A 4-week randomized, double-blind, placebo controlled, parallel group, phase II study to assess the efficacy and safety of gefitinib tablets, 250 mg once daily (OD), in adult patients with moderate chronic obstructive pulmonary disease (COPD) - GECOModerate Chronic Obstructive Pulmonary Disease (COPD)EUCTR2006-000418-20-SEAstraZeneca AB150
进行中（未招募）
不适用
A 4-week randomized, double-blind, placebo controlled, parallel group, phase II study to assess the efficacy and safety of gefitinib tablets, 250 mg once daily (OD), in adult patients with moderate chronic obstructive pulmonary disease (COPD) - GECOEUCTR2006-000418-20-NOAstraZeneca AB150